Two "vice" stocks are among the worst-performing IPOs of 2019. Canadian cannabis producer Sundial Growers (SNDL) is down 82% from its IPO. Greenlane Holdings (GNLN), a national distributor of vape...read more
Sundial Growers, an early-stage Canadian cannabis producer, filed on Friday with the SEC to raise up to $100 million in an initial public offering. Sundial is the second Canadian cannabis grower to file for a US IPO in the past two weeks, following...read more
Renaissance Capital has updated the 2018 US IPO Annual Review with returns through December 31. Download a free Preview of the report, and sign up for IPO market updates delivered to your...read more
The IPO market came back full force this week following the July 4th pause. Nine deals raised a combined $931 million, averaging a gain of 29%. Five biotechs went public, including top performer Allakos, which finished the week up 95%. Tilray grabbed...read more
Vice stocks get a lump of coal: Cannabis and vaping IPOs are among the worst of 2019
Two "vice" stocks are among the worst-performing IPOs of 2019. Canadian cannabis producer Sundial Growers (SNDL) is down 82% from its IPO. Greenlane Holdings (GNLN), a national distributor of vape...read more
Another pot play: Cannabis producer Sundial Growers files for a $100 million US IPO
Sundial Growers, an early-stage Canadian cannabis producer, filed on Friday with the SEC to raise up to $100 million in an initial public offering. Sundial is the second Canadian cannabis grower to file for a US IPO in the past two weeks, following...read more
Renaissance Capital's Updated 2018 US IPO Annual Review
Renaissance Capital has updated the 2018 US IPO Annual Review with returns through December 31. Download a free Preview of the report, and sign up for IPO market updates delivered to your...read more
US IPO Weekly Recap: Bud, biotechs, banks and breast implants make gains in 9-IPO week
The IPO market came back full force this week following the July 4th pause. Nine deals raised a combined $931 million, averaging a gain of 29%. Five biotechs went public, including top performer Allakos, which finished the week up 95%. Tilray grabbed...read more